Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Post time 5 day(s) ago

journal：Clinical Cancer Research

Authors：Neil E. Fleshner; Rashid K. Sayyid; Aaron R. Hansen; Joseph L.K. Chin; Ricardo Fernandes; Eric Winquist; Theodorus van der Kwast; Joan Sweet; Katherine Lajkosz; Miran Kenk; Karen Hersey; Rosette Veloso; Doron Berlin; Jaime O. Herrera-Caceres; Srikala Sridhar; Madeleine Moussa; Antonio Finelli; Robert J. Hamilton; Girish S. Kulkarni; Alexandre R. Zlotta; Anthony M. Joshua

Published date：2023-10-2

DOI：10.1158/1078-0432.ccr-23-0731

PDF link：https://aacrjournals.org/clincan ... 829/ccr-23-0731.pdf

Article link：https://doi.org/10.1158/1078-0432.ccr-23-0731

Article Source：American Association for Cancer Research (AACR)。

Remark：

Post time 5 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AACR] Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AACR] Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial Copy